Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PLAU | P00749 | 3/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353162 | 0.97 | EGFR (0.53) | EGFRCYP19A1CYP11B1CYP11B2RAB9A | |
| SCHEMBL2355805 | 0.92 | PLAU (0.56) | EGFRCYP19A1CYP11B1CYP11B2PLAU | |
| SCHEMBL2350638 | 0.90 | CYP19A1 (0.56) | EGFRCYP19A1CYP11B1CYP11B2MAPT | |
| SCHEMBL12243167 | 0.85 | MAPT (0.59) | MAPTPLAUFFAR4ALDH1A1CYP1A2 | |
| SCHEMBL2362674 | 0.84 | PTGES (0.56) | EGFRMAPTPLAUFFAR4ALDH1A1 | |
| SCHEMBL2311608 | 0.84 | CYP19A1 (0.69) | EGFRCYP19A1CYP11B1CYP11B2PLAU | |
| SCHEMBL9939192 | 0.83 | EGFR (0.51) | EGFRCYP19A1CYP11B1CYP11B2MAPT | |
| SCHEMBL9939493 | 0.82 | CYP11B1 (0.49) | EGFRCYP19A1CYP11B1CYP11B2RAB9A | |
| SCHEMBL12243162 | 0.82 | MAPT (0.54) | MAPTPLAUFFAR4ALDH1A1CYP1A2 | |
| SCHEMBL2357478 | 0.81 | PLAU (0.55) | MAPTPLAUALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| EP-2350119-B1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | UNIQUEST PTY LTD (AU) | 2014-10-29 | — | — | EP | disclosed |
| EP-2350119-B1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | UNIQUEST PTY LTD (AU) | 2014-10-29 | — | — | EP | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| EP-2350119-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | Merlion Pharmaceuticals Pte Ltd. (SG) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010062264-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | MERLION PHARMACEUTICALS PTE LTD (SG) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010062264-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | MERLION PHARMACEUTICALS PTE LTD (SG) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | VIP, LTA, CLPTM1 | EGFR 2123/4885CYP19A1 3018/4885CYP11B1 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.